Low-dose ketamine adjuvant treatment for refractory pain in children, adolescents and young adults with cancer: a pilot study.
Magali CouradeAmandine BertrandLea Guerrini-RousseauAnne PagnierDominique LevyCyril LervatNadine CojeanAlice RibraultSophie DugueSandrine ThouveninChristophe PiguetClaudine SchmittPerrine Marec-BerardPublished in: BMJ supportive & palliative care (2019)
Low doses of ketamine as an adjuvant to opioids significantly reduced the intensity of pain in half of the study population. A tendency towards better pain control is shown, although a lack of statistical power somewhat limits our conclusions, especially in children. Nevertheless, ketamine may be a useful option for improving the treatment of refractory pain in children and AYA with cancer.